Immunovia AB (publ) (STO:IMMNOV)
Sweden · Delayed Price · Currency is SEK 0.1732
-0.0088 (-4.84%)
Mar 4, 2026, 5:29 PM CET
Immunovia AB Revenue
In the year 2025, Immunovia AB had annual revenue of 685.00K SEK, down -26.42%. Immunovia AB had revenue of 354.00K in the quarter ending December 31, 2025, a decrease of -22.20%.
Revenue
685.00K
Revenue Growth
-26.42%
P/S Ratio
170.08
Revenue / Employee
52.69K
Employees
13
Market Cap
116.51M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 685.00K | -246.00K | -26.42% |
| Dec 31, 2024 | 931.00K | -644.00K | -40.89% |
| Dec 31, 2023 | 1.58M | 430.00K | 37.55% |
| Dec 31, 2022 | 1.15M | 301.00K | 35.66% |
| Dec 31, 2021 | 844.00K | 482.00K | 133.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 34.97B |
| Swedish Orphan Biovitrum AB | 28.24B |
| Medicover AB | 25.74B |
| Sectra AB | 3.47B |
| Xbrane Biopharma AB | 152.35M |
| Arcoma AB | 130.80M |
| Ortivus AB | 73.40M |
| IRLAB Therapeutics AB | 57.46M |
Immunovia AB News
- 6 days ago - Immunovia AB (publ) 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 7 days ago - Immunovia AB (IMMVF) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges and ... - GuruFocus
- 7 days ago - Q4 2025 Immunovia AB (publ) Earnings Call Transcript - GuruFocus
- 8 days ago - Immunovia AB (publ) (IMMVF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Immunovia AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Immunovia AB (FRA:1YR) Q3 2025 Earnings Call Highlights: Transition to Commercial Stage with ... - GuruFocus
- 3 months ago - Q3 2025 Immunovia AB (publ) Earnings Call Transcript - GuruFocus
- 3 months ago - Immunovia AB (publ) (IMMVF) Q3 2025 Earnings Call Transcript - Seeking Alpha